TB drug resistance in Canada: Supplementary data

Subscribe to CCDR

Submit a manuscript

About CCDR

Browse

Past issues

Volume 43-11, November 2, 2017: Antimicrobial resistance and One Health

Web exclusive

Tuberculosis drug resistance in Canada: 2006–2016 Supplementary data

V Gallant¹, J Vachon¹*, W Siu¹

Affiliation

¹ Centre for Communicable Disease and Infection Control, Public Health Agency of Canada, Ottawa, ON

Correspondence

tb_surveillance@phac-aspc.gc.ca

Suggested citation

V Gallant, J Vachon, W Siu. Tuberculosis drug resistance in Canada: 2006–2016 Supplementary data. Can Commun Dis Rep. 2017;43(11). Web exclusive. https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2017-43/ccdr-volume-43-11-november-2-2017/tuberculosis-drug-resistance-canada-2006-2016-supplementary-data.html

**Table 1: Total number and percentage of Mycobacterium tuberculosis complex isolates identified with any resistance, as multidrug and extensively drug resistant, by year, 2006-2016, Canada**
Year	Total number of reported MTBC isolates	Resistant to one or more first-line drugs		Multidrug-resistant TB^{Footnote *}		Extensively drug-resistant TB^{Footnote †}
Year	Total number of reported MTBC isolates	n	%	n	%	n	%
2006	1,389	126	9.1	15	1.1	1	0.1
2007	1,267	133	10.5	11	0.9	0	0.0
2008	1,356	116	8.6	15	1.1	1	0.1
2009	1,331	127	9.5	18	1.4	0	0.0
2010	1,274	112	8.8	17	1.3	1	0.1
2011	1,319	139	10.5	18	1.4	1	0.1
2012	1,404	139	9.9	8	0.6	1	0.1
2013	1,371	112	8.2	14	1.0	1	0.1
2014	1,370	130	9.5	18	1.3	1	0.1
2015	1,339	139	10.4	22	1.6	0	0.0
2016	1,452	130	9.0	17	1.2	0	0.0
TOTAL	14,872	1,403	9.4	173	1.2	7	<0.1
Table 1 abbreviations Abbreviations: MTBC, Mycobacterium tuberculosis complex; n, number; TB, tuberculosis Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB Footnote * Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB Return to Table 1 footnote * referrer Footnote † Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second-line drugs (amikacin, capreomycin and kanamycin) Return to Table 1 footnote † referrer

**Table 2: Overall pattern of reported tuberculosis drug resistance in Canada, 2006 to 2016**
Isolate characteristics	Reporting year
	2006		2007		2008		2009		2010		2011		2012		2013		2014		2015		2016		TOTAL
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Total number isolates tested	1,389	100.0	1,267	100.0	1,356	100.0	1,331	100.0	1,274	100.0	1,319	100.0	1,404	100.0	1,371	100.0	1,370	100.0	1,339	100.0	1,452	100.0	14,872	100.0
Isolates tested that were susceptible	1,263	90.9	1,134	89.5	1,240	91.4	1,204	90.5	1,162	91.2	1,180	89.5	1,265	90.1	1,259	91.8	1,240	90.5	1,200	89.6	1,322	91.0	13,469	90.6
Isolates showing any resistance to first-line drugs
Any resistance to isoniazid	101	7.3	110	8.7	102	7.5	113	8.5	101	7.9	122	9.2	111	7.9	93	6.8	106	7.7	110	8.2	113	7.8	1,182	7.9
Any resistance to rifampin	24	1.7	13	1.0	19	1.4	21	1.6	18	1.4	21	1.6	10	0.7	17	1.2	24	1.8	24	1.8	18	1.2	209	1.4
Any resistance to ethambutol	12	0.9	23	1.8	13	1.0	17	1.3	10	0.8	9	0.7	4	0.3	10	0.7	6	0.4	10	0.7	10	0.7	124	0.8
Any resistance to pyrazinamide^{Footnote *}	16	1.5	27	2.7	22	2.1	18	1.7	25	2.4	28	2.3	33	2.8	26	2.2	30	2.6	38	3.4	38	3.0	301	2.0
Total number isolates resistant to one or more first-line TB drugs	126	9.1	133	10.5	116	8.6	127	9.5	112	8.8	139	10.5	139	9.9	112	8.2	130	9.5	139	10.4	130	9.0	1,403	9.4
Monoresistant	107	7.7	111	8.8	94	6.9	98	7.4	88	6.9	119	9.0	128	9.1	93	6.8	107	7.8	114	8.5	108	7.4	1,167	7.8
Multidrug resistant	15	1.1	11	0.9	15	1.1	18	1.4	17	1.3	18	1.4	8	0.6	14	1.0	18	1.3	22	1.6	17	1.2	173	1.2
Polyresi^{Footnote †}stant	3	0.2	11	0.9	6	0.4	11	0.8	6	0.5	1	0.1	2	0.1	4	0.3	4	0.3	3	0.2	5	0.3	56	0.4
Extensively drug resistant^{Footnote ‡}	1	0.1	0	0.0	1	0.1	0	0.0	1	0.1	1	0.1	1	0.1	1	0.1	1	0.1	0	0.0	0	0.0	7	< 0.1
Table 2 abbreviations Abbreviations: n, number; TB, tuberculosis Footnote * Not all isolates were tested for resistance to pyrazinamide. The percentage shown with any resistance is based on the number tested by year: 2006 = 1,080; 2007 = 991; 2008 = 1,048; 2009 = 1,042; 2010 = 1,040; 2011 = 1,197; 2012 = 1,175; 2013 = 1,187; 2014 = 1,142; 2015 =1,113; 2016=1,254 Return to Table 2 footnote * referrer Footnote † Multidrug-resistant tuberculosis (TB) is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB Return to Table 2 footnote † referrer Footnote ‡ Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second–line drugs (amikacin, capreomycin and kanamycin) Return to Table 2 footnote ‡ referrer

**Table 3: Results for routine to anti-tuberculosis drug susceptibility testing of *Mycobacterium tuberculosis* complex isolates originating from Alberta, 2006 to 2016**
Isolate characteristics	Reporting year
	2006		2007		2008		2009		2010		2011		2012		2013		2014		2015		2016
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Isolates tested for resistance to INH, RMP, EMB & PZA^{Footnote *}	104	100.0	98	100.0	134	100.0	159	100.0	107	100.0	156	100.0	163	100.0	154	100.0	181	100.0	185	100.0	206	100.0
Isolates susceptible to all first-line TB drugs	95	91.3	92	93.9	123	91.8	145	91.2	96	89.7	133	85.3	148	90.8	140	90.9	165	91.2	164	88.6	194	94.2
Monoresistant TB
INH	7	6.7	5	5.1	8	6.0	8	5.0	6	5.6	14	9.0	10	6.1	9	5.8	11	6.1	15	8.1	7	3.4
RMP	0	0.0	0	0.0	0	0.0	1	0.6	0	0.0	0	0.0	0	0.0	0	0.0	1	0.6	0	0.0	0	0.0
EMB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
PZA	1	1.0	1	1.0	0	0	3	1.9	0	0	2	1.3	3	1.8	4	2.6	0	0	3	1.6	0	0
Subtotal - Monoresistant TB	8	7.7	6	6.1	8	6.0	12	7.5	6	5.6	16	10.3	13	8.0	13	8.4	12	6.6	18	9.7	7	3.4
Polyresistant
INH & EMB	0	0.0	0	0.0	1	0.8	1.0	0.6	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5
INH & EMB & PZA	0	0	0	0	0	0	0	0	1	0.9	0	0	0	0	1	0.7	0	0	0	0	0	0
INH & PZA	0	0	0	0	0	0	1	0.6	1	0.9	0	0	1	0.6	0	0	0	0	1	0.5	0	0
Subtotal - Polyresistant	0	0.0	0	0.0	1	0.7	2	1.3	2	1.9	0	0.0	1	0.6	1	0.6	0	0.0	1	0.5	1	0.5
Multidrug-resistant TB^{Footnote †}
INH & RMP	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.6	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & PZA	0	0.0	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & PZA & RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.6	0	0.0	0	0.0
INH & RMP & EMB & PZA & SM & ETH & RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5
INH & RMP & EMB & PZA & SM & OFL & MOX	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5	0	0.0
INH & RMP & EMB & PZA & SM & OFL & MOX & ETH & RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.6	0	0.0	0	0.0
INH & RMP & EMB & PZA & SM & RBT	0	0.0	0	0.0	1	0.8	0	0.0	1	0.9	1	0.6	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & SM	1	1.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & SM & ETH & RBT & PAS	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5
INH & RMP & ETH	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5	0	0.0
INH & RMP & ETH & RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	1.3	0	0.0	0	0.0	1	0.6	0	0.0	2	1.0
INH & RMP & PZA & SM & ETH	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.6	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & PZA & SM & OFL & RBT	0	0.0	0	0.0	0	0.0	0	0.0	1	0.9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & PZA & SM & RBT	0	0.0	0	0.0	0	0.0	0	0.0	1	0.9	1	0.6	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.6	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & SM & ETH & RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.6	0	0.0	0	0.0
INH & RMP & SM & RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.6	0	0.0	0	0.0	0	0.0	0	0.0
Subtotal - Multidrug-resistant TB	1	1.0	0	0.0	2	1.5	0	0.0	3	2.8	7	4.5	1	0.6	0	0.0	4	2.2	2	1.1	4	1.9
Extensively drug-resistant TB^{Footnote ‡}
Subtotal - Extensively drug-resistant TB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total number isolates resistant to one or more first-line TB drugs	9	8.7	6	6.1	11	8.2	14	8.8	11	10.3	23	14.7	15	9.2	14	9.1	16	8.8	21	11.4	12	5.8
Table 3 abbreviations Abbreviations: AK, amikacin; EMB, ethambutol; ETH, ethionamide; INH, isoniazid; KM, kanamycin; MOX, moxifloxacin; n, number; OFL, ofloxacin; PAS, para-aminosalicylic acid; PZA, pyrazinamide; RBT, rifabutin; RMP, rifampin; SM, streptomycin; TB, tuberculosis Footnote * Includes Mycobacterium africanum isolate: 1 in 2011, 2013, 2014, 2015 and 2016; 2 in 2007 and 2009, and 3 in 2010; Mycobacterium bovis: 1 in 2012, 2 in 2009, 2011 and 2013, 3 in 2015 Return to Table 3 footnote * referrer Footnote † Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB Return to Table 3 footnote † referrer Footnote ‡ Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second–line drugs (amikacin, capreomycin and kanamycin) Return to Table 3 footnote ‡ referrer

**Table 4: Results for routine to anti-tuberculosis drug susceptibility testing of *Mycobacterium tuberculosis* complex isolates originating from British Columbia, 2006 to 2016**
Isolate characteristics	Reporting year
	2006		2007		2008		2009		2010		2011		2012		2013		2014		2015		2016
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Isolates tested for resistance to INH, RMP, EMB & PZA^{Footnote *}^{Footnote †}	275	100.0	231	100.0	254	100.0	239	100.0	201	100.0	194	100.0	254	100.0	213	100.0	264	100.0	231	100.0	217	100.0
Isolates susceptible to all first-line TB drugs	257	93.5	210	90.9	230	90.6	215	90.0	182	90.6	170	87.6	231	90.9	194	91.1	230	87.1	199	86.2	196	90.3
Monoresistant TB
INH	7	2.6	13	5.6	18	7.1	22	9.2	16	8.0	21	10.8	21	8.3	19	8.9	24	9.1	27	11.7	15	6.9
RMP	6	2.2	0	0.0	3	1.2	1	0.4	0	0.0	1	0.5	0	0.0	0	0.0	2	0.8	1	0.4	0	0.0
EMB	3	1.1	4	1.7	0	0.0	0	0.0	1	0.5	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
PZA	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5	0	0.0	0	0.0	0	0.0	0	0.0	1	0.4	1	0.5
Subtotal - Monoresistant TB	16	5.8	17	7.4	21	8.3	23	9.6	18	9.0	22	11.3	21	8.3	19	8.9	26	9.8	29	12.6	16	7.4
Polyresistant TB
INH & EMB	0	0	2	0.9	0	0.0	1	0.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.4	1	0.5
INH & PZA	0	0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5	0	0.0	0	0.0	2	0.8	0	0.0	2	0.9
Subtotal - Polyresistant TB	0	0.0	2	0.9	0	0.0	1	0.4	0	0.0	1	0.5	0	0.0	0	0.0	2	0.8	1	0.4	3	1.4
Multidrug-resistant TB^{Footnote ‡}
INH & RMP	1	0.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & PZA & KM & CM & ETH & RBT	0	0.0	1	0.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & PZA & PAS	0	0.0	0	0.0	1	0.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & PZA & RBT	0	0.0	0	0.0	1	0.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & PZA & SM & ETH & RBT & PAS	1	0.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & PZA & SM & KM & RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.4	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & PZA & SM & OFL & ETH & RBT & PAS	0	0.0	1	0.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & PZA & SM & OFL & MOX	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5
INH & RMP & EMB & SM & AK & KM & CM & ETH & RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.4	0	0.0
INH & RMP & EMB & SM & ETH & RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.4	0	0.0	0	0.0
INH & RMP & ETH & RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.4	1	0.4	0	0.0
INH & RMP & PZA & RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.4	0	0.0	0	0.0
INH & RMP & PZA & SM & RBT	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5	0	0.0	1	0.4	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & PZA & SM & RBT & PAS	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & RBT	0	0.0	0	0.0	1	0.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	0.8	0	0.0	0	0.0
INH & RMP & SM & RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.4	0	0.0	1	0.5
Subtotal - Multidrug-resistant TB	2	0.7	2	0.9	3	1.2	0	0.0	1	0.5	1	0.5	2	0.8	0	0.0	6	2.3	2	0.9	2	0.9
Extensively drug-resistant ^{Footnote **}
Subtotal - Extensively drug-resistant TB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total number of isolates resistant to one or more first line drugs	18	6.5	21	9.1	24	9.4	24	10.0	19	9.5	24	12.4	23	9.1	19	8.9	34	12.9	32	13.9	21	9.7
Table 4 abbreviations Abbreviations: CM, capreomycin; EMB, ethambutol; ETH, ethionamide; INH, isoniazid; KM, kanamycin; MOX, moxifloxacin; n, number; OFL, ofloxacin; PAS, para-aminosalicylic acid; PZA, pyrazinamide; RBT, rifabutin; RMP, rifampin; SM, streptomycin; TB, tuberculosis Footnote * Includes Mycobacterium bovis isolates: 1 in 2006, 2007 and 2015; Mycobacterium africanum: 1 in 2008, 2009 and 2014; 3 in 2016; 4 in 2015; 5 in 2012 and 2013 Return to Table 4 footnote * referrer Footnote † Routine testing for PZA not conducted in British Columbia Return to Table 4 footnote † referrer Footnote ‡ Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB Return to Table 4 footnote ‡ referrer Footnote Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second–line drugs (amikacin, capreomycin and kanamycin) Return to Table 4 footnote referrer

**Table 5: Results for routine to anti-tuberculosis drug susceptibility testing of *Mycobacterium tuberculosis* complex isolates originating from Manitoba, 2006 to 2016**
Isolate characteristics	Reporting year
	2006		2007		2008		2009		2010		2011		2012		2013		2014		2015		2016
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Isolates tested for resistance to INH, RMP, EMB and PZA^{Footnote *}	119	100.0	84	100.0	116	100.0	106	100.0	113	100.0	97	100.0	123	100.0	148	100.0	125	100.0	129	100.0	168	100
Isolates susceptible to all first-line TB drugs	113	95.0	75	89.3	111	95.7	99	93.4	99	87.6	90	92.8	113	91.9	144	97.3	120	96.0	125	96.9	156	92.3
Monoresistant TB
INH	6	5.0	7	8.3	4	3.4	4	3.8	10	8.8	5	5.2	10	8.1	4	2.7	5	4.0	3	2.3	6	3.6
RMP	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
EMB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
PZA	0	0.0	1	1.2	0	0.0	1	0.9	1	0.9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	3	1.8
Subtotal - Monoresistant TB	6	5.0	8	9.5	4	3.4	5	4.7	11	9.7	5	5.2	10	8.1	4	2.7	5	4.0	3	2.3	9	5.3
Polyresistant TB
INH and EMB	0	0.0	1	1.2	0	0.0	1	0.9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH and PZA	0	0.0	0	0.0	0	0.0	1	0.9	1	0.9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.6
Subtotal - Polyresistant TB	0	0.0	1	1.2	0	0.0	2	1.9	1	0.9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.6
Multidrug-resistant TB^{Footnote †}
INH and RMP	0	0.0	0	0.0	0	0.0	0	0.0	1	0.9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH, RMP, EMB, PZA, SM, AK, KM, CM, ETH and PAS	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	1.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH, RMP, EMB, SM, KM and RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.6
INH, RMP, PZA, ETH and RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.6
INH, RMP, PZA, SM and RBT	0	0.0	0	0.0	1	0.9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH, RMP and RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	1.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH, RMP, SM and RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.8	0	0.0
Subtotal - Multidrug-resistant TB	0	0.0	0	0.0	1	0.9	0	0.0	1	0.9	2	2.1	0	0.0	0	0.0	0	0.0	1	0.8	2	1.2
Extensively drug-resistant^{Footnote ‡}
INH, RMP, EMB, PZA, KM, OFL, ETH and RBT	0	0.0	0	0.0	0	0.0	0	0.0	1	0.9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Subtotal - Extensively drug-resistant TB	0	0.0	0	0.0	0	0.0	0	0.0	1	0.9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total number of isolates resistant to one or more first line drugs	6	5.0	9	10.7	5	4.3	7	6.6	14	12.4	7	7.2	10	8.1	4	2.7	5	4.0	4	3.1	12	7.1
Table 5 abbreviations Abbreviations: AK, amikacin; CM, capreomycin; EMB, ethambutol; ETH, ethionamide; INH, isoniazid; KM, kanamycin; MOX, moxifloxacin; n, number; OFL, ofloxacin; PAS, para-aminosalicylic acid; PZA, pyrazinamide; RBT, rifabutin; RMP, rifampin; SM, streptomycin; TB, tuberculosis Footnote * Includes Mycobacterium bovis isolates: 1 in 2006 and 2007; Mycobacterium africanum: 1 in 2008 Return to Table 5 footnote * referrer Footnote † Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB Return to Table 5 footnote † referrer Footnote ‡ Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second–line drugs (amikacin, capreomycin and kanamycin) Return to Table 5 footnote ‡ referrer

**Table 6: Results for routine to anti-tuberculosis drug susceptibility testing of *Mycobacterium tuberculosis* complex isolates originating from New Brunswick, 2006 to 2016**
Isolate characteristics	Reporting year
	2006		2007		2008		2009		2010		2011		2012		2013		2014		2015		2016
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Isolates tested for resistance to INH, RMP, EMB & PZA^{Footnote *}	3	100.0	5	100.0	3	100.0	10	100.0	9	100.0	5	100.0	4	100.0	3	100.0	6	100.0	7	100.0	9	100.0
Isolates susceptible to all first-line TB drugs	3	100.0	5	100.0	3	100.0	10	100.0	7	77.8	5	100.0	3	75.0	2	66.7	6	100.0	5	71.4	0	0.0
Monoresistant TB
INH	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	33.3	0	0.0	0	0.0	0	0.0
RMP	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
EMB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
PZA	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	25.0	0	0.0	0	0.0	1	14.3	0	0.0
Subtotal - Monoresistant TB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	25.0	1	33.3	0	0.0	1	14.3	0	0.0
Polyresistant TB
Subtotal - Polyresistant TB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Multidrug-resistant TB^{Footnote †}
INH & RMP & PZA & ETH & RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	14.3	0	0.0
Subtotal - Multidrug-resistant TB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	14.3	0	0.0
Extensively drug-resistant^{Footnote ‡}
Subtotal - Extensively drug-resistant TB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total number of isolates resistant to one or more first line drugs	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	25.0	1	33.3	0	0.0	2	28.6	0	0.0
Table 6 abbreviations Abbreviations: EMB,ethambutol; ETH, ethionamide; INH, isoniazid; n, number; PZA, pyrazinamide; RBT, rifabutin; RMP, rifampin; TB, tuberculosis Footnote * Includes one Mycobacterium africanum isolate for 2007 Return to Table 6 footnote * referrer Footnote † Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB Return to Table 6 footnote † referrer Footnote ‡ Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second–line drugs (amikacin, capreomycin and kanamycin) Return to Table 6 footnote ‡ referrer

**Table 7: Results for routine to anti-tuberculosis drug susceptibility testing of *Mycobacterium tuberculosis* complex isolates originating from Newfoundland and Labrador, 2006 to 2016**
Isolate characteristics	Reporting year
	2006		2007		2008		2009		2010		2011		2012		2013		2014		2015		2016
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Isolates tested for resistance to INH, RMP, EMB & PZA	11	100.0	5	100.0	5	100.0	10	100.0	9	100.0	5	100.0	5	100.0	11	100.0	6	100.0	21	100.0	18	100.0
Isolates susceptible to all first-line TB drugs	11	100.0	5	100.0	5	100.0	10	100.0	9	100.0	5	100.0	5	100.0	11	100.0	6	100.0	21	100.0	18	100.0
Monoresistant TB
INH	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
RMP	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
EMB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
PZA	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Subtotal - Monoresistant TB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Polyresistant TB
Subtotal - Polyresistant TB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Multidrug-resistant TB^{Footnote *}
Subtotal - Multidrug-resistant TB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Extensively drug-resistant^{Footnote †}
Subtotal - Extensively drug-resistant TB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total number of isolates resistant to one or more first line drugs	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Table 7 abbreviations Abbreviations: EMB, ethambutol; INH, isoniazid; n, number; PZA, pyrazinamide; RMP, rifampin; TB, tuberculosis Footnote * Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB Return to Table 7 footnote * referrer Footnote † Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second–line drugs (amikacin, capreomycin and kanamycin) Return to Table 7 footnote † referrer

**Table 8: Results for routine to anti-tuberculosis drug susceptibility testing of *Mycobacterium tuberculosis* complex isolates originating from Northwest Territories, 2006 to 2016**
Isolate characteristics	Reporting year
	2006		2007		2008		2009		2010		2011		2012		2013		2014		2015		2016
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Isolates tested for resistance to INH, RMP, EMB & PZA	4	100.0	14	100.0	13	100.0	10	100.0	5	100.0	8	100.0	6	100.0	3	100.0	2	100.0	4	100.0	4	100.0
Isolates susceptible to all first-line TB drugs	3	75.0	14	100.0	13	100.0	9	90.0	4	80.0	8	100.0	6	100.0	3	100.0	2	100.0	4	100.0	4	100.0
Monoresistant TB
INH	1	25.0	0	0.0	0	0.0	0	0.0	1	20.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
RMP	0	0.0	0	0.0	0	0.0	1	10.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
EMB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
PZA	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Subtotal - Monoresistant TB	1	25.0	0	0.0	0	0.0	1	10.0	1	20.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Polyresistant TB
Subtotal - Polyresistant TB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Multidrug-resistant TB^{Footnote *}
Subtotal - Multidrug-resistant TB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Extensively drug-resistant^{Footnote †}
Subtotal - Extensively drug-resistant TB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total number of isolates resistant to one or more first line drugs	1	25.0	0	0.0	0	0.0	1	10.0	1	20.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Table 8 abbreviations Abbreviations: EMB, ethambutol; INH, isoniazid; n, numnber; PZA, pyrazinamide; RMP, rifampin; TB, tuberculosis Footnote * Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB Return to Table 8 footnote * referrer Footnote † Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second–line drugs (amikacin, capreomycin and kanamycin) Return to Table 8 footnote † referrer

**Table 9: Results for routine to anti-tuberculosis drug susceptibility testing of *Mycobacterium tuberculosis* complex isolates originating from Nova Scotia, 2006 to 2016**
Isolate characteristics	Reporting year
	2006		2007		2008		2009		2010		2011		2012		2013		2014		2015		2016
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Isolates tested for resistance to INH, RMP, EMB & PZA^{Footnote *}	8	100.0	5	100.0	3	100.0	7	100.0	8	100.0	7	100.0	9	100.0	9	100.0	8	100.0	7	100.0	3	100.0
Isolates susceptible to all first-line TB drugs	8	100.0	5	100.0	3	100.0	7	100.0	5	62.5	7	100.0	9	100.0	8	88.9	5	62.5	7	100.0	2	66.7
Monoresistant TB
INH	0	0.0	0	0.0	0	0.0	0	0.0	1	12.5	0	0.0	0	0.0	1	11.1	3	37.5	0	0.0	0	0.0
RMP	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
EMB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
PZA	0	0.0	0	0.0	0	0.0	0	0.0	1	12.5	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	33.3
Subtotal - Monoresistant TB	0	0.0	0	0.0	0	0.0	0	0.0	2	25.0	0	0.0	0	0.0	1	11.1	3	37.5	0	0.0	1	33.3
Polyresistant
INH & PZA	0	0.0	0	0.0	0	0.0	0	0.0	1	12.5	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Subtotal - Polyresistant TB	0	0.0	0	0.0	0	0.0	0	0.0	1	12.5	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Multidrug-resistant TB^{Footnote †}
Subtotal - Multidrug-resistant TB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Extensively drug-resistant^{Footnote ‡}
Subtotal - Extensively drug-resistant TB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total number of isolates resistant to one or more first line drugs	0	0.0	0	0.0	0	0.0	0	0.0	3	37.5	0	0.0	0	0.0	1	11.1	3	37.5	0	0.0	1	33.3
Table 9 abbreviations Abbreviations: EMB, ethambutol; INH, isoniazid; n, number; PZA, pyrazinamide; RMP, rifampin; TB, tuberculosis Footnote * Includes one Mycobacterium bovis isolate for 2010 Return to Table 9 footnote * referrer Footnote † Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB Return to Table 9 footnote † referrer Footnote ‡ Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second–line drugs (amikacin, capreomycin and kanamycin) Return to Table 9 footnote ‡ referrer

**Table 10: Results for routine to anti-tuberculosis drug susceptibility testing of *Mycobacterium tuberculosis* complex isolates originating from Nunavut, 2006 to 2016**
Isolate characteristics	Reporting year
	2005		2006		2007		2008		2009		2010		2011		2012		2013		2014		2015		2016
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Isolates tested for resistance to INH, RMP, EMB & PZA	28	100.0	37	100.0	25	100.0	51	100.0	50	100.0	71	100.0	64	100.0	65	100.0	42	100.0	66	100.0	35	100.0	33	100.0
Isolates susceptible to all first-line TB drugs	28	100.0	37	100.0	24	96.0	51	100.0	49	98.0	70	98.6	62	96.9	65	100.0	42	100.0	66	100.0	33	94.3	33	100.0
Monoresistant TB
INH	0	0.0	0	0.0	1	4.0	0	0.0	1	2.0	1	1.4	1	1.6	0	0.0	0	0.0	0	0.0	2	5.7	0	0.0
RMP	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	1.6	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
EMB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
PZA	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Subtotal - Monoresistant TB	0	0.0	0	0.0	1	4.0	0	0.0	1	2.0	1	1.4	2	3.1	0	0.0	0	0.0	0	0.0	2	5.7	0	0.0
Polyresistant TB
Subtotal - Polyresistant TB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Multi-resistant TB^{Footnote *}
Subtotal - Multidrug-resistant TB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Extensively drug-resistant TB^{Footnote †}
Subtotal - Extensively drug-resistant TB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total number of isolates resistant to one or more first line drugs	0	0.0	0	0.0	1	4.0	0	0.0	1	2.0	1	1.4	2	3.1	0	0.0	0	0.0	0	0.0	2	5.7	0	0.0
Table 10 abbreviations Abbreviations: EMB, ethambutol; INH, isoniazid; n, number; PZA, pyrazinamide; RMP, rifampin; TB, tuberculosis Footnote * Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB Return to Table 10 footnote * referrer Footnote † Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second–line drugs (amikacin, capreomycin and kanamycin) Return to Table 10 footnote † referrer

**Table 11: Results for routine to anti-tuberculosis drug susceptibility testing of *Mycobacterium tuberculosis* complex isolates originating from Ontario, 2006 to 2016**
Isolate characteristics	Reporting year
	2006		2007		2008		2009		2010		2011		2012		2013		2014		2015		2016
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Isolates tested for resistance to INH, RMP, EMB & PZA^{Footnote *}	567	100.0	538	100.0	479	100.0	488	100.0	496	100.0	507	100.0	493	100.0	511	100.0	457	100.0	480	100.0	505	100.0
Isolates susceptible to all first-line TB drugs	504	88.9	466	86.6	427	89.1	428	87.7	456	91.9	454	89.6	429	87.0	458	89.6	407	89.1	421	87.7	453	89.7
Monoresistant TB
INH	39	6.9	50	9.3	33	6.9	39	8.0	27	5.4	39	7.7	45	9.1	27	5.3	30	6.6	30	6.3	43	8.5
RMP	1	0.2	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	2	0.4	1	0.2	0	0.0	1	0.2
EMB	0	0.0	1	0.2	1	0.2	1	0.2	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0
PZA	9	1.6	9	1.7	6	1.3	4	0.8	2	0.4	6	1.2	10	2.0	8	1.6	11	2.4	15	3.1	1	0.2
Subtotal - Monoresistant TB	49	8.6	61	11.3	40	8.4	44	9.0	29	5.8	45	8.9	57	11.6	37	7.2	42	9.2	45	9.4	45	8.9
Polyresistant TB
EMB & PZA	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & EMB	3	0.7	1	0.2	2	0.4	3	0.6	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0
INH & EMB & PZA	0	0.0	0	0.0	2	0.4	2	0.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & PZA	0	0.0	2	0.4	0	0.0	0	0.0	1	0.2	0	0.0	1	0.2	2	0.4	1	0.2	0	0.0	0	0.0
Subtotal - Polyresistant TB	3	0.5	4	0.7	4	0.8	5	1.0	1	0.2	0	0.0	1	0.2	3	0.6	1	0.2	0	0.0	0	0.0
Multidrug-resistant TB^{Footnote *}
INH & RMP	2	0.4	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2
INH & RMP & AK & CM & RBT	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & CM & RBT	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & ETH & RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	1	0.2
INH & RMP & EMB & PZA & AK & CM & ETH & RBT	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & PZA & CM & RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & PZA & ETH & RBT	0	0.0	2	0.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & PZA & RBT	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	1	0.2	0	0.0
INH & RMP & EMB & PZA & RBT & PAS	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & PZA & SM	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & PZA & SM & AK & KM & CM & RBT & PAS	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0
INH & RMP & EMB & PZA & SM & ETH & RBT	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	1	0.2	0	0.0	1	0.2	0	0.0	0	0.0	1	0.2
INH & RMP & EMB & PZA & SM & ETH & RBT & PAS	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & PZA & SM & OFL & MOX & ETH & RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & PZA & SM & OFL & MOX & RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2
INH & RMP & EMB & PZA & SM & RBT	0	0.0	1	0.2	1	0.2	1	0.2	0	0.0	1	0.2	0	0.0	1	0.2	0	0.0	3	0.6	0	0.0
INH & RMP & EMB & RBT	1	0.4	1	0.2	1	0.2	2	0.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & SM & AK & CM	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & SM & ETH & RBT	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & SM & ETH & RBT & PAS	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & SM & KM & RBT & PAS	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & SM & OFL & ETH & RBT	0	0.0	0	0.0	0	0.0	1	0.2	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & SM & OFL & MOX & ETH & RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & SM & RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	1	0.2	0	0.0	1	0.2
INH & RMP & ETH & RBT	2	0.4	0	0.0	1	0.2	1	0.2	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	1	0.2	0	0.0
INH & RMP & ETH & RBT & PAS	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & OFL & ETH & RBT & PAS	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & PAS	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2
INH & RMP & PZA & ETH & RBT	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & PZA & SM & AK & KM & CM & ETH & RBT & PAS	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0
INH & RMP & PZA & SM & ETH & RBT	0	0.0	1	0.2	1	0.2	1	0.2	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0
INH & RMP & PZA & SM & OFL & MOX & RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & PZA & SM & RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	1	0.2	1	0.2	0	0.0	1	0.2
INH & RMP & RBT	1	0.2	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	2	0.4	0	0.0	0	0.0	0	0.0
INH & RMP & SM	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	1	0.2	0	0.0	0	0.0	0	0.0
INH & RMP & SM & CM & RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0
INH & RMP & SM & ETH & RBT	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0
INH & RMP & SM & ETH & RBT & PAS	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0
INH & RMP & SM & KM & ETH & RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & SM & OFL & ETH & RBT	0	0.0	0	0.0	0	0.0	1	0.2	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & SM & RBT	0	0.0	0	0.0	3	0.6	1	0.2	1	0.2	1	0.2	1	0.2	2	0.4	1	0.2	5	1.0	0	0.0
Subtotal - Multidrug-resistant TB	10	1.8	7	1.3	7	1.5	11	2.3	10	2.0	7	1.4	5	1.0	13	2.5	6	1.3	14	2.9	7	1.4
Extensively drug-resistant TB^{Footnote †}
INH & RMP & AK & CM & OFL & ETH & RBT	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & PZA & CM & OFL & ETH & RBT & PAS	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & PZA & SM & KM & OFL & MOX & ETH & RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & PZA & SM & KM & OFL & MOX & ETH & RBT & PAS	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & PZA & SM & KM & OFL & MOX & RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0
Subtotal - Extensively drug-resistant TB	1	0.2	0	0.0	1	0.2	0	0.0	0	0.0	1	0.2	1	0.2	0	0.0	1	0.2	0	0.0	0	0.0
Total number of isolates resistant to one or more first line drugs	63	11.1	72	13.4	52	10.9	60	12.3	40	8.1	53	10.5	64	13.0	53	10.4	50	10.9	59	12.3	52	10.3
Table 11 abbreviations Abbreviations: CM, capreomycin; EMB, ethambutol; ETH, ethionamide; INH, isoniazid; KM, kanamycin; MOX, moxifloxacin; n, number; OFL, ofloxacin; PAS, para-aminosalicylic acid; PZA, pyrazinamide; RBT, rifabutin; RMP, rifampin; SM, streptomycin; TB, tuberculosis Footnote * Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB Return to Table 11 footnote * referrer Footnote † Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second–line drugs (amikacin, capreomycin and kanamycin) Return to Table 11 footnote † referrer

**Table 12: Results for routine to anti-tuberculosis drug susceptibility testing of Mycobacterium tuberculosis complex isolates originating from Prince Edward Island, 2006 to 2016**
Isolate characteristics	Reporting year
	2006		2007		2008		2009		2010		2011		2012		2013		2014		2015		2016
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Isolates tested for resistance to INH, RMP, EMB & PZA	0	0	0	0	0	0	1	100.0	1	100.0	3	100.0	0	0	0	0	2	100.0	2	100.0	4	100.0
Isolates susceptible to all first-line TB drugs	0	0	0	0	0	0	1	100.0	1	100.0	2	66.7	0	0	0	0	2	100.0	2	100.0	4	100.0
Monoresistant TB
INH	0	0	0	0	0	0	0	0.0	0	0.0	0	0.0	0	0	0	0	0	0.0	0	0.0	0	0.0
RMP	0	0	0	0	0	0	0	0.0	0	0.0	0	0.0	0	0	0	0	0	0.0	0	0.0	0	0.0
EMB	0	0	0	0	0	0	0	0.0	0	0.0	0	0.0	0	0	0	0	0	0.0	0	0.0	0	0.0
PZA	0	0	0	0	0	0	0	0.0	0	0.0	1	33.3	0	0	0	0	0	0.0	0	0.0	0	0.0
Subtotal - Monoresistant TB	0	0	0	0	0	0	0	0.0	0	0.0	1	33.3	0	0	0	0	0	0.0	0	0.0	0	0.0
Polyresistant TB
Subtotal - Polyresistant TB	0	0	0	0	0	0	0	0.0	0	0.0	0	0.0	0	0	0	0	0	0.0	0	0.0	0	0.0
Multidrug-resistant TB^{Footnote *}
Subtotal - Multidrug-resistant TB	0	0	0	0	0	0	0	0.0	0	0.0	0	0.0	0	0	0	0	0	0.0	0	0.0	0	0.0
Extensively drug-resistant TB^{Footnote †}
Subtotal - Extensively drug-resistant TB	0	0	0	0	0	0	0	0.0	0	0.0	0	0.0	0	0	0	0	0	0.0	0	0.0	0	0.0
Total number of isolates resistant to one or more first line drugs	0	0	0	0	0	0	0	0.0	0	0.0	1	33.3	0	0	0	0	0	0.0	0	0.0	0	0.0
Table 12 abbreviations Abbreviations: EMB, ethambutol; INH, isoniazid; n, number; PZA, pyrazinamide; RMP, rifampin; TB, tuberculosis Footnote * Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB Return to Table 12 footnote * referrer Footnote † Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second–line drugs (amikacin, capreomycin and kanamycin) Return to Table 12 footnote † referrer

**Table 13: Results for routine to anti-tuberculosis drug susceptibility testing of Mycobacterium tuberculosis complex isolates originating from Quebec, 2006 to 2016**
Isolate characteristics	Reporting year
	2006		2007		2008		2009		2010		2011		2012		2013		2014		2015		2016
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Isolates tested for resistance to INH, RMP, EMB and PZA^{Footnote *}	201	100.0	200	100.0	210	100.0	171	100.0	197	100.0	205	100.0	209	100.0	205	100.0	186	100.0	185	100.0	215	100
Isolates susceptible to all first-line TB drugs	173	86.1	177	88.5	188	89.5	156	91.2	179	90.9	180	87.8	187	89.5	187	91.2	167	89.8	167	90.3	187	87.0
Monoresistant TB
INH	21	10.4	12	6.0	15	7.1	7	4.1	11	5.6	18	8.8	13	6.2	12	5.9	10	5.4	8	4.3	17	7.9
RMP	1	0.5	1	0.5	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5	0	0.0
EMB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
PZA	4	2.0	4	2.0	4	1.9	2	1.2	5	2.5	6	2.9	9	4.3	4	2.0	7	3.8	6	3.2	9	4.2
Subtotal - Monoresistant TB	26	12.9	17	8.5	19	9.0	9	5.3	16	8.1	24	11.7	22	10.5	16	7.8	17	9.1	15	8.1	26	12.1
Polyresistant TB
INH and EMB	0	0.0	3	1.5	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5	0	0.0
INH and PZA	0	0.0	1	0.5	1	0.5	0	0.0	1	0.5	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Subtotal - Polyresistant TB	0	0.0	4	2.0	1	0.5	0	0.0	1	0.5	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5	0	0.0
Multidrug-resistant TB^{Footnote †}
INH & RMP & EMB & ETH & RBT	1	0.5	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & PZA	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5	0	0.0
INH & RMP & EMB & PZA & RBT	0	0.0	0	0.0	0	0.0	1	0.6	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & PZA & SM & ETH	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & PZA & SM & KM & ETH & RBT & PAS	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & PZA & SM & RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & RBT	0	0.0	1	0.5	0	0.0	1	0.6	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & EMB & SM & RBT	1	0.5	1	0.5	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & ETH & RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5	0	0.0
INH & RMP & PZA & RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5	0	0.0	0	0.0
INH & RMP & PZA & SM & AK & KM & CM	0	0.0	0	0.0	1	0.5	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & PZA & SM & ETH & RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5
INH & RMP & PZA & SM & KM & CM & ETH	0	0.0	0	0.0	0	0.0	1	0.6	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & RBT	0	0.0	0	0.0	0	0.0	1	0.6	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5
INH & RMP & SM & RBT	0	0.0	0	0.0	1	0.5	2	1.2	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5	0	0.0	0	0.0
Subtotal - Multidrug-resistant TB	2	1.0	2	1.0	2	1.0	6	3.5	1	0.5	1	0.5	0	0.0	1	0.5	2	1.1	2	1.1	2	0.9
Extensively drug-reistant TB^{Footnote ‡}
INH, RMP, EMB, PZA, SM, AK, KM, CM, OFL, MOX, ETH and RBT	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5	0	0.0	0	0.0	0	0.0
Subtotal - Extensively drug-resistant TB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5	0	0.0	0	0.0	0	0.0
Total number of isolates resistant to one or more first line drugs	28	13.9	23	11.5	22	10.5	15	8.8	18	9.1	25	12.2	22	10.5	18	8.8	19	10.2	18	9.7	28	15.1
Table 13 abbreviations Abbreviations: AK, amikacin; CM, capreomycin; ETH, ethionamide; KM, kanamycin; MOX, moxifloxacin; n, number; OFL, ofloxacin; PAS, para-aminosalicylic acid; RBT, rifabutin; RMP, rifampin; SM, streptomycin; TB, tuberculosis Footnote * Includes Mycobacterium bovis isolates: 1 in 2007, 2009, 2013 and 2014; 2 in 2006 and 2010; 3 in 2011 and 2016; 4 in 2012; Mycobacterium caprae: 1 in 2006; Mycobacterium africanum: 1 in 2006, 2008, and 2014; 2 in 2007, 2012, and 2013; 3 in 2009 and 2011; 4 in 2010; and 5 in 2015 and 2016 Return to Table 13 footnote * referrer Footnote † Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB Return to Table 13 footnote † referrer Footnote ‡ Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second–line drugs (amikacin, capreomycin and kanamycin) Return to Table 13 footnote ‡ referrer

**Table 14: Results for routine to anti-tuberculosis drug susceptibility testing of *Mycobacterium tuberculosis* complex isolates originating from Saskatchewan, 2006 to 2016**
Isolate characteristics	Reporting year
	2006		2007		2008		2009		2010		2011		2012		2013		2014		2015		2016
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Isolates tested for resistance to INH, RMP, EMB & PZA	58	100.0	60	100.0	81	100.0	77	100.0	54	100.0	66	100.0	72	100.0	71	100.0	63	100.0	50	100.0	65	100.0
Isolates susceptible to all first-line TB drugs	57	98.3	59	98.3	79	97.5	72	93.5	51	94.4	62	93.9	68	94.4	69	97.2	60	95.2	49	98.0	62	95.4
Monoresistant TB
INH	1	1.7	1	1.7	2	2.5	3	3.9	2	3.7	4	6.1	1	1.4	1	1.4	0	0.0	0	0.0	2	3.1
RMP	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	1.6	0	0.0	0	0.0
EMB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
PZA	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	3	4.2	1	1.4	1	1.6	1	2.0	1	1.5
Subtotal - Monoresistant TB	1	1.7	1	1.7	2	2.5	3	3.9	2	3.7	4	6.1	4	5.6	2	2.8	2	3.2	1	2.0	3	4.6
Polyresistant TB
INH & EMB	0	0.0	0	0.0	0	0.0	1	1.3	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & PZA	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	1.6	0	0.0	0	0.0
Subtotal - Polyresistant TB	0	0.0	0	0.0	0	0.0	1	1.3	0	0.0	0	0.0	0	0.0	0	0.0	1	1.6	0	0.0	0	0.0
Multidrug-resistant TB^{Footnote *}
INH & RMP & RBT	0	0.0	0	0.0	0	0.0	0	0.0	1	1.9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
INH & RMP & SM	0	0.0	0	0.0	0	0.0	1	1.3	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Subtotal - Multidrug-resistant TB	0	0.0	0	0.0	0	0.0	1	1.3	1	1.9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Extensively drug-resistant TB^{Footnote †}
Subtotal - Extensively drug-resistant TB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total number of isolates resistant to one or more first line drugs	1	1.7	1	1.7	2	2.5	5	6.5	3	5.6	4	6.1	4	5.6	2	2.8	3	4.8	1	2.0	3	4.6
Table 14 abbreviations Abbreviations: EMB, ethambutol; INH, isoniazid; n, number; PZA, pyrazinamide; RBT, rifabutin; RMP, rifampin; SM, streptomycin; TB, tuberculosis Footnote * Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB Return to Table 14 footnote * referrer Footnote † Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second–line drugs (amikacin, capreomycin and kanamycin) Return to Table 14 footnote † referrer

**Table 15: Results for routine to anti-tuberculosis drug susceptibility testing of *Mycobacterium tuberculosis* complex isolates originating from Yukon, 2006 to 2016**
Isolate characteristics	Reporting year
	2006		2007		2008		2009		2010		2011		2012		2013		2014		2015		2016
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Isolates tested for resistance to INH, RMP, EMB & PZA^{Footnote *}	2	100.0	2	100.0	7	100.0	3	100.0	5	100.0	2	100.0	1	100.0	1	100.0	4	100.0	3	100.0	2	100.0
Isolates susceptible to all first-line TB drugs	2	100.0	2	100.0	7	100.0	3	100.0	5	100.0	2	100.0	1	100.0	1	100.0	4	100.0	3	100.0	2	100.0
Monoresistant TB
Subtotal - Monoresistant TB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Polyresistant TB
Subtotal - Polyresistant TB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Multidrug-resistant TB^{Footnote †}
Subtotal - Multidrug-resistant TB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Extensively drug-reistant TB^{Footnote ‡}
Subtotal - Extensively drug-resistant TB	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total number of isolates resistant to one or more first line drugs	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Table 15 abbreviations Abbreviations: EMB, ethambutol; INH, isoniazid; n, number; PZA, pyrazinamide; RMP, rifampin; TB, tuberculosis Footnote * Routine testing for PZA not conducted for Yukon Return to Table 15 footnote * referrer Footnote † Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB Return to Table 15 footnote † referrer Footnote ‡ Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second–line drugs (amikacin, capreomycin and kanamycin) Return to Table 15 footnote ‡ referrer

**Table 16: Total number of *Mycobacterium tuberculosis* complex isolates by reporting and originating province/territory, 2016**
Reporting province/territory^{Footnote *}	Canada	Originating province/territory
Reporting province/territory^{Footnote *}	Canada	N.L.	P.E.I.	N.S.	N.B.	Que.	Ont.	Man.	Sask.	Alta.	B.C.	Y.T.	N.W.T	Nvt.
N.L.	18	18	0	0	0	0	0	0	0	0	0	0	0	0
N.S.	7	0	4	3	0	0	0	0	0	0	0	0	0	0
N.B.	9	0	0	0	9	0	0	0	0	0	0	0	0	0
Que.	215	0	0	0	0	215	0	0	0	0	0	0	0	0
Ont.	536	0	0	0	0	3	504	0	0	0	0	0	0	29
Man.	168	0	0	0	0	0	0	168	0	0	0	0	0	0
Sask.	63	0	0	0	0	0	0	0	63	0	0	0	0	0
Alta.	216	0	0	0	0	0	0	0	2	206	0	0	4	4
B.C.	220	0	0	0	0	0	1	0	0	0	217	2	0	0
TOTAL	1,452	18	4	3	9	218	505	168	65	206	217	2	4	33
Table 16 abbreviations Abbreviations: Alta., Alberta; B.C., British Columbia; Man., Manitoba; N.B., New Brunswick; N.L., Newfoundland and Labrador; N.S., Nova Scotia; Nvt., Nunavut; N.W.T., Northwest Territories; Ont., Ontario; P.E.I., Prince Edward Island; Que., Quebec; Sask., Saskatchewan; Y.T., Yukon Footnote * Not all provinces and territories have the capacity to perform drug susceptibility testing. Those without the capacity prepare the isolates and forward them to other provincial laboratories for testing. In some instances, the laboratory that tests the sample (reporting province) sends the results to Public Health Agency of Canada (PHAC) on behalf of the originating province or territory Return to Table 16 footnote * referrer

**Table 17: Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis isolates by province/territory of origin, 2016**
Isolate characteristics	Canada	Originating province/territory
Isolate characteristics	Canada	N.L.	P.E.I.	N.S.	N.B.	Que.	Ont.	Man.	Sask.	Alta.	B.C.	Y.T.	N.W.T	Nvt.
INH & RMP	6	0	0	0	0	1	2	0	0	2	1	0	0	0
INH & RMP & EMB	4	0	0	0	0	0	2	1	0	1	0	0	0	0
INH & RMP & EMB & PZA	4	0	0	0	0	0	2	0	0	1	1	0	0	0
INH & RMP & PZA	3	0	0	0	0	1	1	1	0	0	0	0	0	0
Total number of Multidrug-resistant TB^{Footnote *}	17	0	0	0	0	2	7	2	0	4	2	0	0	0
Extensively drug-resistant TB^{Footnote †}	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Table 17 abbreviations Abbreviations: Alta., Alberta; B.C., British Columbia; EMB, ethambutol; INH, isoniazid; Man., Manitoba; N.B., New Brunswick; N.L., Newfoundland and Labrador; N.S., Nova Scotia; Nvt., Nunavut; N.W.T., Northwest Territories; Ont., Ontario; P.E.I., Prince Edward Island; PZA, pyrazinamide; Que., Quebec; RMP, rifampin; Sask., Saskatchewan; TB, tuberculosis; Y.T., Yukon Footnote * Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB Return to Table 17 footnote * referrer Footnote † Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second-line drugs (amikacin, capreomycin and kanamycin) Return to Table 17 footnote † referrer

**Table 18: Provincial/territorial breakdown by any resistance, multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis in Canada, 2006 to 2016**
Originating province/territory	Total number of reported MTBC Isolates	Resistant to one or more first-line drugs		Multidrug-resistant TB^{Footnote *}		Extensively drug-resistant TB^{Footnote †}
Originating province/territory	Total number of reported MTBC Isolates	Number	Percent (%)	Number	Percent (%)	Number	Percent (%)
Ontario	5,521	618	11.2	97	1.8	5	0.1
British Columbia	2,573	259	10.1	21	0.8	0	0.0
Quebec	2,187	237	10.8	21	1.0	1	0.0
Alberta	1,647	152	9.2	24	1.5	0	0.0
Manitoba	1,328	83	6.3	7	0.5	1	0.1
Saskatchewan	717	29	4.0	2	0.3	0	0.0
Nunavut	537	7	1.3	0	0.0	0	0.0
Newfoundland and Labrador	106	0	0.0	0	0.0	0	0.0
Nova Scotia	74	8	10.8	0	0.0	0	0.0
Northwest Territories	73	3	4.1	0	0.0	0	0.0
New Brunswick	64	6	9.4	1	1.6	0	0.0
Yukon	32	0	0.0	0	0.0	0	0.0
Prince Edward Island	13	1	7.7	0	0.0	0	0.0
Canada	14,872	1,403	9.4	173	1.2	7	0.0
Table 18 abbreviations Abbreviations: MTBC, Mycobacterium tuberculosis complex; TB, tuberculosis Footnote * Multidrug-resistant TB is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant TB Return to Table 18 footnote * referrer Footnote † Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second–line drugs (amikacin, capreomycin and kanamycin) Return to Table 18 footnote † referrer

**Table 19: Tuberculosis drug resistance by sex and age group in Canada, 2016**
Age group and sex		Isolates reported		Resistant to one or more first-line drugs		Multidrug resistant^{Footnote *}		Extensively drug resistant^{Footnote †}
Age group and sex		Number	Percent (%)	Number	Percent (%)	Number	Percent (%)	Number	Percent (%)
< 1	Male	1	0.1	0	0.0	0	0.0	0	0.0
	Female	1	0.1	0	0.0	0	0.0	0	0.0
	Unknown	0	0.0	0	0.0	0	0.0	0	0.0
	Total	2	0.1	0	0.0	0	0.0	0	0.0
1 to 4	Male	5	0.3	0	0.0	0	0.0	0	0.0
	Female	6	0.4	0	0.0	0	0.0	0	0.0
	Unknown	0	0.0	1	0.8	0	0.0	0	0.0
	Total	11	0.8	1	0.8	0	0.0	0	0.0
5 to 14	Male	11	0.8	1	0.8	0	0.0	0	0.0
	Female	11	0.8	3	2.3	1	5.9	0	0.0
	Unknown	0	0.0	0	0.0	0	0.0	0	0.0
	Total	22	1.5	4	3.1	1	5.9	0	0.0
15 to 24	Male	112	7.7	11	8.5	1	5.9	0	0.0
	Female	95	6.5	14	10.8	3	17.6	0	0.0
	Unknown	0	0.0	0	0.0	0	0.0	0	0.0
	Total	207	14.3	25	19.2	4	23.5	0	0.0
25 to 34	Male	126	8.7	8	6.2	2	11.8	0	0.0
	Female	160	11.0	18	13.8	2	11.8	0	0.0
	Unknown	0	0.0	0	0.0	0	0.0	0	0.0
	Total	286	19.7	26	20.0	4	23.5	0	0.0
35 to 44	Male	98	6.7	6	4.6	0	0.0	0	0.0
	Female	84	5.8	12	9.2	4	23.5	0	0.0
	Unknown	0	0.0	0	0.0	0	0.0	0	0.0
	Total	182	12.5	18	13.8	4	23.5	0	0.0
45 to 54	Male	104	7.2	11	8.5	1	5.9	0	0.0
	Female	71	4.9	5	3.8	1	5.9	0	0.0
	Unknown	1	0.1	0	0.0	0	0.0	0	0.0
	Total	176	12.1	16	12.3	2	11.8	0	0.0
55 to 64	Male	111	7.6	14	10.8	2	11.8	0	0.0
	Female	49	3.4	4	3.1	0	0.0	0	0.0
	Unknown	1	0.1	0	0.0	0	0.0	0	0.0
	Total	161	11.1	18	13.8	2	11.8	0	0.0
65 to 74	Male	88	6.1	1	0.8	0	0.0	0	0.0
	Female	75	5.2	2	1.5	0	0.0	0	0.0
	Unknown	0	0.0	0	0.0	0	0.0	0	0.0
	Total	163	11.2	3	2.3	0	0.0	0	0.0
75+	Male	135	9.3	12	9.2	0	0.0	0	0.0
	Female	106	7.3	7	5.4	0	0.0	0	0.0
	Unknown	0	0.0	0	0.0	0	0.0	0	0.0
	Total	241	16.6	19	14.6	0	0.0	0	0.0
Unknown	Male	1	0.1	0	0.0	0	0.0	0	0.0
	Female	0	0.0	0	0.0	0	0.0	0	0.0
	Unknown	0	0.0	0	0.0	0	0.0	0	0.0
	Total	1	0.1	0	0.0	0	0.0	0	0.0
Total	Male	792	54.5	64	49.2	6	35.3	0	0.0
	Female	658	45.3	65	50.0	11	64.7	0	0.0
	Unknown	2	0.1	1	0.8	0	0.0	0	0.0
TOTAL		1,452	100.0	130	100.0	17	100.0	0	0.0
Footnote * Multidrug-resistant tuberculosis (TB) is TB that is resistant to isoniazid and rifampin, but does not meet the definition of extensively drug-resistant tuberculosis (TB) Return to Table 19 footnote * referrer Footnote † Extensively drug-resistant TB is TB that is resistant to isoniazid and rifampin, any fluoroquinolone and at least one of three injectable second–line drugs (amikacin, capreomycin and kanamycin) Return to Table 19 footnote † referrer

Table of contents

Report a problem or mistake on this page

Please select all that apply:

A link, button or video is not working

It has a spelling mistake

Information is missing

Information is outdated or wrong

I can't find what I'm looking for

Other issue not in this list

Date modified:: 2019-04-02

Language selection

Search